FDA 面临对涉嫌财务冲突和有偏见观点的专家小组的审查。 FDA faces scrutiny over expert panels with alleged financial conflicts and biased views.

美国食品和药物管理局因创建特设专家小组而面临批评，其成员在抗抑郁药和更年期药物等话题上存在财务冲突和边缘观点。 The US FDA is facing criticism for creating ad hoc expert panels with members who have financial conflicts and fringe views on topics like antidepressants and menopause drugs. 批评者认为,由林业发展局专员马蒂·马卡里领导的这些小组可能绕过联邦透明度规则,提倡与卫生部长罗伯特·肯尼迪(Robert F. Kennedy Jr.)一致的观点,而不是反映普遍的科学共识。 Critics argue these panels, led by FDA Commissioner Marty Makary, may be skirting federal transparency rules and promoting viewpoints that align with Health Secretary Robert F. Kennedy Jr., rather than reflecting general scientific consensus. 如果用于监管决策, 这可能会使FDA面临法律挑战. This could expose the FDA to legal challenges if used for regulatory decisions.